lifestyle.thedishh.com

Author: NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

February 24, 2026
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

February 17, 2026
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

January 26, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

January 22, 2026
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

January 15, 2026
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

December 22, 2025
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

December 18, 2025
Neurocrine Biosciences to Host R&D Day on December 16

December 10, 2025
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

October 29, 2025